Your browser doesn't support javascript.
loading
Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma.
Okada, Takuro; Fushimi, Chihiro; Matsuki, Takashi; Okamoto, Isaku; Sato, Hiroki; Kondo, Takahito; Tokashiki, Kunihiko; Kishida, Takuma; Ito, Tatsuya; Yamashita, Gai; Aihara, Yusuke; Hanyu, Kenji; Kushihashi, Yukiomi; Masubuchi, Tatsuo; Tada, Yuichiro; Miura, Kouki; Harada, Yuki; Momiyama, Kaho; Yamashita, Taku; Omura, G O; Takahashi, Hideaki; Oridate, Nobuhiko; Tsukahara, Kiyoaki.
Afiliação
  • Okada T; Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan takuhns@tokyo-med.ac.jp.
  • Fushimi C; Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
  • Matsuki T; Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
  • Okamoto I; Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
  • Sato H; Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
  • Kondo T; Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
  • Tokashiki K; Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
  • Kishida T; Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
  • Ito T; Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
  • Yamashita G; Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
  • Aihara Y; Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
  • Hanyu K; Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
  • Kushihashi Y; Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
  • Masubuchi T; Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
  • Tada Y; Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
  • Miura K; Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
  • Harada Y; Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
  • Momiyama K; Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
  • Yamashita T; Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
  • Omura GO; Department of Head and Neck Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Takahashi H; Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, Yokohama, Japan.
  • Oridate N; Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, Yokohama, Japan.
  • Tsukahara K; Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Anticancer Res ; 42(3): 1607-1613, 2022 Mar.
Article em En | MEDLINE | ID: mdl-35220258
ABSTRACT
BACKGROUND/

AIM:

There are no real-world comparative data of nivolumab doses of 3 mg/kg and 240 mg/body for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We investigated the efficacy and safety of nivolumab in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) at different doses using real-world data. PATIENTS AND

METHODS:

R/M SCCHN patients who received nivolumab were divided into the 3 mg/kg and 240 mg/body groups and retrospectively examined for efficacy and safety.

RESULTS:

A total of 199 patients (3 mg/kg and 240 mg/body, 88 and 111 patients, respectively) were included. The 3 mg/kg vs. 240 mg/body groups had similar overall response rates (15% vs. 25, p=0.15), disease control rates (46% vs. 57%, p=0.15), overall survival (9.5 months vs. 10.9 months), and progression-free survival (3.7 months vs. 3.8 months, p=0.95). The incidence of immune-related adverse events was also similar in both groups.

CONCLUSION:

In R/M SCCHN patients, nivolumab showed similar efficacy and safety at doses of 3 mg/kg and 240 mg/body.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas de Cabeça e Pescoço / Nivolumabe / Inibidores de Checkpoint Imunológico / Neoplasias de Cabeça e Pescoço / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas de Cabeça e Pescoço / Nivolumabe / Inibidores de Checkpoint Imunológico / Neoplasias de Cabeça e Pescoço / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article